{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:04:34Z","timestamp":1787843074760,"version":"build-2784847793"},"reference-count":130,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of the cases. Despite advancements in targeted therapies and immunotherapies, many patients still rely on chemotherapy, highlighting the need for innovative treatment strategies. Bispecific antibodies (bsAbs), which feature two distinct binding sites capable of targeting different antigens, have emerged as a promising therapeutic approach, particularly in combination with chemotherapy. This review explores the scientific evolution and clinical application of bsAbs in NSCLC, focusing on their synergistic potential with chemotherapy. BsAbs, such as amivantamab, which targets EGFR and MET, have demonstrated significant efficacy in clinical trials, particularly in patients with EGFR mutations. The combination of bsAbs with chemotherapy enhances immune-mediated tumor destruction by modulating the tumor microenvironment and overcoming resistance mechanisms. Recent clinical trials have shown improved progression-free survival and overall survival when bsAbs such as amivantamab are combined with chemotherapy, underscoring their potential to transform NSCLC treatment. Many other clinical trials are underway that are evaluating newer bsAbs, such as ivonescimab, which targets PD1 and VEGF. This review also discusses ongoing clinical trials investigating various bsAbs targeting EGFR, PD-1, PD-L1, HER2, and other pathways, highlighting the future directions of bsAb-based therapies. As the field evolves, bsAbs are poised to become a cornerstone of multimodal NSCLC treatment, offering more effective and personalized therapeutic options for patients with advanced disease.<\/jats:p>","DOI":"10.3390\/curroncol32040206","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:08:40Z","timestamp":1743505720000},"page":"206","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-534X","authenticated-orcid":false,"given":"Saqib Raza","family":"Khan","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, Canada"},{"name":"Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7621","authenticated-orcid":false,"given":"Daniel","family":"Breadner","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, Canada"},{"name":"Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2024, September 30). Estimated Number of New Cases and Deaths from 2022 to 2045, Mortality, Both Sexes. Available online: https:\/\/gco.iarc.who.int\/tomorrow\/en\/dataviz\/tables?cancers=15&populations=900&types=1&years=2045."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","first-page":"1","article-title":"Prevalence of driver mutations in non-small-cell lung cancers in the People\u2019s Republic of China","volume":"5","author":"Gou","year":"2014","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Reck, M., Ciuleanu, T.-E., Schenker, M., Bordenave, S., Cobo, M., Juan-Vidal, O., Reinmuth, N., Richardet, E., Felip, E., and Menezes, J. (2024). Five-Year Outcomes with First-Line (1L) Nivolumab+ Ipilimumab+ Chemotherapy (N+ I+ C) vs. C in Patients (pts) with Metastatic NSCLC (mNSCLC) in CheckMate 9LA, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2024.42.16_suppl.8560"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Belaroussi, Y., Bouteiller, F., Bellera, C., Pasquier, D., Perol, M., Debieuvre, D., Filleron, T., Girard, N., Schott, R., and Mathoulin-P\u00e9lissier, S. (2023). Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36623-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Arasanz, H., Chocarro, L., Fern\u00e1ndez-Rubio, L., Blanco, E., Bocanegra, A., Echaide, M., Labiano, I., Huerta, A.E., Alsina, M., and Vera, R. (2023). Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129855"},{"key":"ref_11","first-page":"103","article-title":"Five-year overall survival and prognostic factors in patients with lung cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015","volume":"55","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"980250","article-title":"scFv antibody: Principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"J. Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/S0264-410X(03)00050-1","article-title":"CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation","volume":"21","author":"Scheper","year":"2003","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ygyno.2003.10.032","article-title":"Characterization of an anti-human ovarian carcinoma\u00d7 anti-human CD3 bispecific single-chain antibody with an albumin-original interlinker","volume":"92","author":"Fang","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: Bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs\u2013past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_27","first-page":"155","article-title":"The emerging role of new protein scaffold-based agents for treatment of cancer","volume":"10","author":"Weidle","year":"2013","journal-title":"Cancer Genom. Proteom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1074\/jbc.M007734200","article-title":"Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs","volume":"276","author":"Conrath","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jim.2006.07.019","article-title":"Dimerisation strategies for shark IgNAR single domain antibody fragments","volume":"315","author":"Simmons","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hao, S., Xu, S., Li, L., Li, Y., Zhao, M., Chen, J., Zhu, S., Xie, Y., Jiang, H., and Zhu, J. (2022). Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10165-7"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/protein\/9.3.299","article-title":"Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody","volume":"9","author":"Holliger","year":"1996","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0161-5890(96)00097-1","article-title":"Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase","volume":"33","author":"Atwell","year":"1996","journal-title":"Mol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1380-2933(97)00010-9","article-title":"Enzyme immunoassays using bispecific diabodies","volume":"3","author":"Kontermann","year":"1997","journal-title":"Immunotechnology"},{"key":"ref_34","first-page":"525","article-title":"Anti-HLA-DR\/anti-DOTA diabody construction in a modular gene design platform: Bispecific antibodies for pretargeted radioimmunotherapy","volume":"16","author":"DeNardo","year":"2001","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"\u201cDiabodies\u201d: Small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1358\/dnp.2009.22.8.1413783","article-title":"Diabodies: Molecular engineering and therapeutic applications","volume":"22","author":"Wu","year":"2009","journal-title":"Drug News Perspect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2022-CT003","article-title":"Abstract CT003: Innate cell engager (ICE\u00ae) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory\/relapsed CD30+ lymphoma","volume":"82","author":"Nieto","year":"2022","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.4049\/jimmunol.165.12.7050","article-title":"Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives","volume":"165","author":"Schoonjans","year":"2000","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1389-0344(01)00066-1","article-title":"A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain","volume":"17","author":"Schoonjans","year":"2001","journal-title":"Biomol. Eng."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0022-1759(02)00148-5","article-title":"Fab-scFv fusion protein: An efficient approach to production of bispecific antibody fragments","volume":"267","author":"Lu","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/19420862.2015.1022694","article-title":"Fab-based bispecific antibody formats with robust biophysical properties and biological activity","volume":"7","author":"Wu","year":"2015","journal-title":"MAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2011.01.020","article-title":"Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells","volume":"303","author":"Kellner","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13568-016-0201-4","article-title":"A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells","volume":"6","author":"Li","year":"2016","journal-title":"AMB Express"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","article-title":"ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells","volume":"63","author":"Bossi","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4049\/jimmunol.148.5.1547","article-title":"Formation of a bispecific antibody by the use of leucine zippers","volume":"148","author":"Kostelny","year":"1992","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-12-1012","article-title":"Single-domain antibody\u2013based and linker-free bispecific antibodies targeting Fc\u03b3RIII induce potent antitumor activity without recruiting regulatory T cells","volume":"12","author":"Rozan","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tips.2012.06.001","article-title":"Complex and defined biostructures with the dock-and-lock method","volume":"33","author":"Rossi","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"Muller","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0076-6879(86)21019-8","article-title":"[17] Bispecific monoclonal antibodies from hybrid hybridomas","volume":"Volume 121","author":"Suresh","year":"1986","journal-title":"Methods in Enzymology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4161\/mabs.2.3.11791","article-title":"Structural and functional characterization of the trifunctional antibody catumaxomab","volume":"2","author":"Chelius","year":"2010","journal-title":"MAbs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","article-title":"Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library","volume":"270","author":"Atwell","year":"1997","journal-title":"J. Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","article-title":"Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells","volume":"74","author":"Junttila","year":"2014","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"19637","DOI":"10.1074\/jbc.M110.117382","article-title":"Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG","volume":"285","author":"Gunasekaran","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1074\/jbc.M114.620260","article-title":"A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism","volume":"290","author":"Liu","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"MAbs"},{"key":"ref_57","first-page":"649","article-title":"Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob\u2013Knob and Hole\u2013Hole side products","volume":"30","author":"Kuglstatter","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2011.09.003","article-title":"A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies","volume":"20","author":"Schaefer","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20850","DOI":"10.1074\/jbc.M110.113910","article-title":"Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling","volume":"285","author":"Jackman","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jmb.2009.08.032","article-title":"The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators","volume":"393","author":"Dimasi","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.abb.2012.03.016","article-title":"Development of tetravalent IgG1 dual targeting IGF-1R\u2013EGFR antibodies with potent tumor inhibition","volume":"526","author":"Croasdale","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1074\/jbc.M513415200","article-title":"Single variable domain-IgG fusion: A novel recombinant approach to Fc domain-containing bispecific antibodies","volume":"281","author":"Shen","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gu, J., Yang, J., Chang, Q., Liu, Z., Ghayur, T., and Gu, J. (2015). Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124135"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/protein\/gzs096","article-title":"A series of anti-CEA\/anti-DOTA bispecific antibody formats evaluated for pre-targeting: Comparison of tumor uptake and blood clearance","volume":"26","author":"Yazaki","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"MAbs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00432-015-1949-7","article-title":"A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR","volume":"141","author":"Zeng","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","article-title":"A phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance","volume":"29","author":"Yap","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: First approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","unstructured":"(2024, October 31). FDA Grants Accelerated Approval to Talquetamab-Tgvs for Relapsed or Refractory Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_79","unstructured":"(2024, October 31). FDA Grants Accelerated Approval to Elranatamab-Bcmm for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma."},{"key":"ref_80","unstructured":"(2024, October 31). FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."},{"key":"ref_81","unstructured":"(2024, October 31). A Study of Lazertinib as Monotherapy or in Combination with Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer (Chrysalis-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04077463?cond=NCT04077463&rank=1."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Shu, C.A., Goto, K., Ohe, Y., Besse, B., Lee, S.-H., Wang, Y., Griesinger, F., Yang, J.C.-H., Felip, E., and Sanborn, R.E. (2022). Amivantamab and Lazertinib in Patients with EGFR-Mutant Non\u2013Small Cell Lung (NSCLC) After Progression on Osimertinib and Platinum-Based Chemotherapy: Updated Results from CHRYSALIS-2, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2022.40.16_suppl.9006"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Cho, B.C., Wang, Y., Felip, E., Cui, J., Spira, A.I., Neal, J.W., Baik, C., Marmarelis, M.E., Ichihara, E., and Lee, J.-S. (2024). Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results from CHRYSALIS-2, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2024.42.16_suppl.8516"},{"key":"ref_84","unstructured":"(2024, October 31). FDA Approves Lazertinib with Amivantamab-Vmjw for Non-Small Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer."},{"key":"ref_85","unstructured":"(2024, October 31). Amivantamab Combo Shows Improved OS Trend vs. Osimertinib in EGFR+ NSCLC. Available online: https:\/\/www.cancernetwork.com\/view\/amivantamab-combo-shows-improved-os-trend-vs-osimertinib-in-egfr-nsclc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lim, P.T., Goh, B.H., and Lee, W.-L. (2022). Taxol: Mechanisms of action against cancer, an update with current research. Paclitaxel, Elsevier.","DOI":"10.1016\/B978-0-323-90951-8.00007-2"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1758834016644155","article-title":"Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes","volume":"8","author":"Tomasini","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Merlano, M.C., Denaro, N., Galizia, D., Ruatta, F., Occelli, M., Minei, S., Abbona, A., Paccagnella, M., Ghidini, M., and Garrone, O. (2022). How chemotherapy affects the tumor immune microenvironment: A narrative review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081822"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.esmoop.2024.102586","article-title":"7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC","volume":"9","author":"Veillon","year":"2024","journal-title":"ESMO Open"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S1244","DOI":"10.1016\/j.annonc.2024.08.2296","article-title":"LBA54 Amivantamab plus chemotherapy vs. chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2","volume":"35","author":"Popat","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/JCO.2024.42.16_suppl.8508","article-title":"Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_98","unstructured":"Chennapragada, S.S., and Ramadas, P. (2024). Bispecific antibody toxicity. StatPearls, StatPearls Publishing."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: Will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_101","unstructured":"(2024, October 31). A Phase I Clinical Study of HS-20117 in Participants with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05940116?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=1&rank=9."},{"key":"ref_102","unstructured":"(2024, October 31). Study of MCLA-129 Combined with Befotertinib in the Treatment of Advanced Non-Small Cell Lung Cancer with EGFR Sensitive Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06015568?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=4&rank=31."},{"key":"ref_103","unstructured":"(2024, October 31). Phase 1\/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04868877?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=4&rank=34."},{"key":"ref_104","unstructured":"(2024, October 31). A Dose Escalation with Expansion Study of EMB-01 in Participants with Advanced\/Metastatic Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03797391?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=4&rank=38."},{"key":"ref_105","unstructured":"(2024, October 31). A Trial to Find Out How Safe REGN7075 Is and How Well It Works in Combination with Cemiplimab for Adult Participants with Advanced Cancers (COMBINE-EGFR-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04626635?cond=REGN7075&term=bispecific%20antibody&rank=1."},{"key":"ref_106","unstructured":"(2024, October 31). HLX35(EGFR\u00d74-1BB Bispecific) in Patients with Advanced or Metastatic Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05360381?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=2&rank=19."},{"key":"ref_107","unstructured":"(2024, October 31). A Study of SI-B001, an EGFR\/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04603287?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=5&rank=48."},{"key":"ref_108","unstructured":"(2024, October 31). A Study of TAK-186 (Also Known as MVC-101) in Adults with Advanced or Metastatic Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04844073?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=7&rank=64."},{"key":"ref_109","unstructured":"(2024, October 31). Efficacy of Cadonilimab in Non-Squamous Non-Small Cell Lung Cancer Patients Resistant to EGFR-TKI, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06277674?cond=NCT06277674&rank=1."},{"key":"ref_110","unstructured":"(2024, October 31). Study of Cadonilimab Combined with Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer Patients with Untreated Brain Metastases (CBC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05812534?cond=NCT05812534&rank=1."},{"key":"ref_111","unstructured":"(2024, October 31). Study of KN046 in Subjects with Advanced Non-Small Cell Lung Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05420220?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=3&rank=25."},{"key":"ref_112","unstructured":"(2024, October 31). A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants with Metastatic Non-Small Cell Lung Cancer. (eVOLVE-Lung02), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05984277?cond=volrustomig&rank=5."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1016\/j.jtho.2024.09.506","article-title":"P2. 14B. 05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma","volume":"19","author":"Scherpereel","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_114","unstructured":"(2024, October 31). A Study of SI-B001+SI-B003\u00b1 Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05949606?cond=SIB003&rank=7."},{"key":"ref_115","unstructured":"(2024, October 31). MGD019 DART\u00ae Protein in Unresectable\/Metastatic Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03761017?cond=MGD019&rank=1."},{"key":"ref_116","unstructured":"(2024, October 31). Study of Vudalimab or Pembrolizumab in Combination with Chemotherapy as First-Line Treatment in Patients with Advanced NSCLC, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06173505?cond=XmAb20717&rank=7."},{"key":"ref_117","unstructured":"(2024, October 31). A Study of PM8002 (Anti-PD-L1\/VEGF) in Combination with Chemotherapy in Patients with NSCLC, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05756972?cond=PM8002&page=2&rank=11."},{"key":"ref_118","unstructured":"(2024, October 31). A Trial of AK112 (PD1\/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04736823?cond=NSCLC&intr=AK112&page=1&rank=1."},{"key":"ref_119","unstructured":"(2024, October 31). AK112 Plus Platinum-Based Chemotherapy for EGFR\/ALK\/ROS1 Positve NSCLC (Apple), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06196814?cond=NSCLC&intr=AK112&page=1&rank=7."},{"key":"ref_120","unstructured":"(2024, October 31). A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06412471?cond=SSGJ-707&intr=NSCLC&rank=1."},{"key":"ref_121","unstructured":"(2024, October 31). A Study of Zenocutuzumab (MCLA-128) in Patients with Solid Tumors Harboring an NRG1 Fusion (eNRGy), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02912949?cond=MCLA128&intr=NSCLC&rank=1."},{"key":"ref_122","unstructured":"(2024, October 31). Trial of ZW25 (Zanidatamab) in Patients with Advanced HER2-Expressing Cancers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02892123?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=8&rank=72."},{"key":"ref_123","unstructured":"(2024, October 31). First in Human Study of NVG-111 in Relapsed\/Refractory ROR1+ Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04763083?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=5&rank=49."},{"key":"ref_124","unstructured":"(2024, October 31). Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination with Pembrolizumab in Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05585034?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=6&rank=60."},{"key":"ref_125","unstructured":"(2024, October 31). GEN1047 for Solid Tumors-First in Human (FIH) Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05180474?cond=Non-small%20Cell%20Lung%20Cancer&term=Bispecific%20Antibody&page=7&rank=65."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-20-0985","article-title":"Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors","volume":"20","author":"Gordon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_129","unstructured":"(2024, October 31). A Study of ABT-165 in Subjects with Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01946074?cond=ABT-165&rank=1."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"S828","DOI":"10.1016\/j.annonc.2024.08.1359","article-title":"1302P MET \u00d7 MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study","volume":"35","author":"Cho","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/206\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:07:05Z","timestamp":1760029625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040206"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040206","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}